Mycophenolatmofetil Al (Mycophenolate Mofetil)

Mycophenolate mofetil blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides in lymphocytes. This inhibition reduces the availability of DNA building blocks, thereby suppressing the proliferation of B and T cells that drive transplant rejection.

The appropriate dose of Mycophenolatmofetil Al is determined by the prescribing physician based on the type of transplant, patient weight, renal function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber's instructions and local guidelines.

Safety data for mycophenolate mofetil in pregnancy and lactation are limited, and the drug is generally contraindicated because of potential teratogenic effects. Women of child‑bearing potential should use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mycophenolate mofetil differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcium‑dependent signaling pathways. It offers a distinct side‑effect profile, with less nephrotoxicity but a higher risk of gastrointestinal upset and bone‑marrow suppression, making it a valuable component of combination regimens.

The product should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keeping the medication in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Mycophenolatmofetil Al is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The exact administration schedule—such as twice‑daily dosing—depends on the individual treatment plan and should be followed precisely.

Serious risks include profound leukopenia or neutropenia, which can predispose patients to severe infections, as well as rare occurrences of hepatic dysfunction and malignancies such as lymphomas. Patients should be monitored regularly for blood‑count changes and signs of infection.

Mycophenolatmofetil Al is contraindicated in patients with known hypersensitivity to mycophenolate mofetil or any of its excipients, in those with active uncontrolled infections, and in pregnant women due to teratogenic potential. Caution is also advised for individuals with severe hepatic impairment.